The global financial landscape has undergone a seismic shift as 2025 closed with merger and acquisition (M&A) volumes surpassing a staggering $5 trillion. This "M&A Renaissance" marks a definitive end to the deal-making drought that plagued 2023 and much of 2024, signaling a return to bold, transformative corporate
Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of early 2026, the San Diego-based biotech has transitioned from a promising "dark horse" into a formidable contender challenging the global duopoly of Eli Lilly (NYSE: [...]
Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats.
However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.
Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally underscores the company's status as the undisputed titan of the large-cap healthcare sector, a position bolstered by
As the first month of 2026 draws to a close, the narrative that dominated Wall Street for the better part of three years—the undisputed reign of mega-cap technology—is rapidly fracturing. In its place, a massive "sector rotation" is taking hold, fundamentally altering the landscape for institutional and retail
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year downturn that plagued the market between 2022 and 2024. This resurgence is not merely a product of
Nvidia is a tech stock that has outpaced the broader markets by a significant margin over the past decade. Is NVDA still a good buy as Jensen Huang prepares to visit China?
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 3.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy designation for its drug, sofetabart mipitecan, intended to treat a specific type of ovarian cancer.
NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2025 revenues of $24.56 billion on Wednesday, January 21, 2026, soundly beating Wall Street’s expectations. The healthcare giant accompanied its earnings beat with a bold 2026 financial forecast, projecting
In a move that signals the arrival of the "Bio-Computing" era, NVIDIA (NASDAQ: NVDA) and Eli Lilly (NYSE: LLY) have officially launched a landmark $1 billion AI co-innovation lab. Announced during the J.P. Morgan Healthcare Conference in January 2026, the five-year partnership represents a massive bet on the convergence of generative AI and life sciences. [...]
Eli Lilly's stock is experiencing short-term volatility due to its proximity to a 52-week high and upcoming earnings, amid strong analyst support and mixed technical indicators.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with Zoetis (NYSE:ZTS).
